BRIEF-Merit Medical’S Wrapsody Wave Trial Exceeds Performance Goals For Arteriovenous Graft Patients

Reuters
25 Nov 2024
BRIEF-Merit Medical’S Wrapsody Wave Trial Exceeds Performance Goals For Arteriovenous Graft Patients

Nov 25 (Reuters) - Merit Medical Systems Inc MMSI.O:

  • MERIT MEDICAL’S WRAPSODY WAVE TRIAL EXCEEDS PERFORMANCE GOALS FOR ARTERIOVENOUS GRAFT (AVERAGE) PATIENTS

  • MERIT MEDICAL SYSTEMS INC - WRAPSODY DEVICE SHOWS 81.4% EFFICACY IN WAVE TRIAL

  • MERIT MEDICAL SYSTEMS INC - 95.4% OF AVERAGE PATIENTS FREE FROM ADVERSE EVENTS IN WAVE TRIAL

  • MERIT MEDICAL SYSTEMS INC - WRAPSODY DEVICE NOT APPROVED FOR COMMERCIAL DISTRIBUTION IN U.S.

Source text: ID:nGNX9HqrWP

Further company coverage: MMSI.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10